Canaccord Genuity Maintains Buy on Ventyx Biosciences, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Edward Nash maintains a Buy rating on Ventyx Biosciences (NASDAQ:VTYX) but lowers the price target from $15 to $14.
August 12, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity analyst Edward Nash maintains a Buy rating on Ventyx Biosciences but lowers the price target from $15 to $14.
The maintained Buy rating suggests continued confidence in Ventyx Biosciences' prospects, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100